Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 10/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.31 |
| ▸ | CNR1 | P21554 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1685478 | 0.83 | KDM4E (0.39) | ALDH1A1MAPTMAPK1MEN1KMT2A | |
| Pinoxaden SCHEMBL29359629 | 0.79 | ELANE (0.33) | ALDH1A1MAPTMAPK1MEN1KMT2A | |
| SCHEMBL5078713 | 0.78 | HSD17B10 (0.38) | ALDH1A1MAPTMAPK1MEN1KMT2A | |
| SCHEMBL22940089 | 0.78 | MEN1 (0.30) | ALDH1A1MAPTMAPK1MEN1KMT2A | |
| Pinoxaden SCHEMBL17187932 | 0.75 | KMT2A (0.32) | ALDH1A1MAPTMAPK1MEN1KMT2A | |
| SCHEMBL24643264 | 0.74 | MAPT (0.34) | ALDH1A1MAPTMAPK1KMT2AKDM4E | |
| SCHEMBL22959624 | 0.71 | RAB9A (0.34) | ALDH1A1MAPTMAPK1MEN1KMT2A | |
| SCHEMBL14088267 | 0.70 | SYK (0.33) | ALDH1A1MEN1KMT2AKDM4ETP53 | |
| SCHEMBL1685479 | 0.69 | KDM4E (0.36) | KDM4ELMNA | |
| SCHEMBL1685480 | 0.69 | CNR2 (0.34) | KDM4ECNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220064184-A1 | METHOD FOR PREPARING 2-ARYLMALONIC ACID DERIVATIVE AND INTERMEDIATE, AND USE THEREOF | ORIENTAL(LUZHOU) AGROCHEMICALS CO., LTD. (CN) | 2022-03-03 | — | — | US | disclosed |
| US-20220017437-A1 | HALOGENATED CONJUGATED DIENE COMPOUND, AND PREPARATION AND APPLICATION THEREOF | ORIENTAL(LUZHOU) AGROCHEMICALS CO., LTD. (CN) | 2022-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220064184-A1 | METHOD FOR PREPARING 2-ARYLMALONIC ACID DERIVATIVE AND INTERMEDIATE, AND USE THEREOF | CYP2A6, CYP2B6, CYP2A13 | ALDH1A1 67/4885MAPT 4810/4885MAPK1 3083/4885 |
| US-20220017437-A1 | HALOGENATED CONJUGATED DIENE COMPOUND, AND PREPARATION AND APPLICATION THEREOF | CYP19A1, CYP2A6, CYP21A2 | ALDH1A1 15/4885MAPT 4703/4885MAPK1 1556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.